Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous monitoring system app, leading the FDA to issue its most serious recall notice. | Dexcom has been hit by a major ...

A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to update the ...

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...

DexCom (DXCM) shares are in the spotlight after the company delivered better-than-expected second quarter revenues. However, a softer full-year outlook has drawn investor caution. Sector-wide trade ...

If you’re trying to figure out whether now’s the time to buy, hold, or even sell DexCom stock, you’re not alone. After all, its share price has been a bit of a roller coaster lately. Over the last ...

The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. This story was originally published on MedTech Dive. To receive daily news and insights, ...

InvestingPro analysis reveals that DexCom maintains a healthy current ratio of 1.52 and operates with moderate debt levels, suggesting strong operational stability. DexCom faces what Piper Sandler ...

Investors focused on Dexcom’s lower gross margin of 61.3%, down about 170 basis points year-over-year, despite record revenue ...

The company’s strong financial health score of "GREAT" on InvestingPro supports this outlook, with robust cash flows and moderate debt levels. TD Cowen expects DexCom’s upcoming third-quarter results ...

San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a ...

13 analysts have expressed a variety of opinions on DexCom (NASDAQ:DXCM) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot of their ...